Tremfya Market: Expanding Role of IL-23 Inhibitors in Autoimmune Disease Management
The increasing Tremfya drug market growth, expanding guselkumab market, and ongoing advancements in the psoriasis treatment market are transforming the management of chronic immune-mediated diseases. Tremfya (guselkumab), an interleukin-23 (IL-23) inhibitor, has become an important biologic therapy for conditions such as plaque psoriasis, psoriatic arthritis, ulcerative colitis, and...
0 Kommentare 0 Geteilt 39 Ansichten 0 Bewertungen